Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E4.3 - NASH-TAG 2022 Wrap-up: NITs from The FDA and Patients' Perspectives
Description: Last weekend's NASH-TAG 2022 was the best attended event in the conference's six-year history, and probably the one that will have the greatest long-term impact on diagnosis, treatment and monitoring of Fatty Liver patients. In this wrap-up conversation, our seven-person panel (including two Pharma execs and one diagnostics entrepreneur) considers how two key stakeholders -- FDA regulators and patients -- might respond to changes in clinical trial protocols that remove or de-emphasize biopsy-generated data.This conversation is a continuation of 4.2, which focused on the NASH-TAG "fireside chats." This one starts with Erin Quirk's observation that events of the...